INFLAMMATORY BREAST CANCER
Clinical trials for INFLAMMATORY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new INFLAMMATORY BREAST CANCER trials appear
Sign up with your email to follow new studies for INFLAMMATORY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New chemo combo shows promise for tough breast cancer
Disease control OngoingThis study tested a chemotherapy combination (carboplatin and nab-paclitaxel) given before surgery to people with a fast-growing type of breast cancer called triple negative. The goal was to shrink tumors enough so that no cancer remains at the time of surgery. The study included…
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New combo shows promise against tough breast cancer
Disease control OngoingThis study tests a new drug called onvansertib combined with standard chemotherapy (paclitaxel) in people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating to see if the combination is safe and c…
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Antonio Giordano, MD • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
Immunotherapy boosts chemo for rare breast cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can improve outcomes for people with HER2-negative inflammatory breast cancer, a rare and aggressive type. About 52 participants will receive either chemo alone or chemo plus pembrolizum…
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for rare, aggressive breast cancer: drug combo shows promise before surgery
Disease control OngoingThis study tested a drug called eribulin combined with standard chemotherapy given before surgery for a rare and aggressive type of breast cancer called HER2-negative inflammatory breast cancer. The goal was to see if this approach could eliminate all signs of cancer in the breas…
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 22, 2026 13:54 UTC